期刊文献+

山莨菪碱联合血浆置换治疗血栓性血小板减少性紫癜中血小板变化的意义 被引量:3

Significance of platelet changes in thrombotic thrombocytopenic purpura patients by treatment of anisodamine combined with plasma exchange
下载PDF
导出
摘要 目的探讨血小板变化在山莨菪碱联合血浆置换治疗血栓性血小板减少性紫癜(TTP)中的临床意义。方法将本院收治的78例TTP患者随机分为2组,每组39例。研究组给予山莨菪碱联合血浆置换治疗,对照组仅给予血浆置换治疗,疗程均为21 d。观察2组治疗前及治疗后第2、5、12、21天血小板计数的变化及不良反应发生情况,并比较临床疗效。结果研究组治愈率显著高于对照组,且总有效率有高于对照组的趋势。治疗后第2、5、12、21天,2组血小板计数均较治疗前明显增多;治疗后第2、5、12天,研究组血小板计数显著多于对照组,差异有统计学意义。治疗期间,2组均未见严重不良反应。结论血浆置换联合山莨菪碱能有效加速TTP患者血小板的恢复,减少血小板消耗及微血栓形成,疗效显著,且安全性较好。 Objective To explore the clinical significance of platelet changes in thrombotic thrombocytopenic purpura (TTP)patients by treatment of anisodamine combined with plasma ex-change.Methods 78 patients with TTP were randomly divided into two groups,39 cases in each group.The research group was treated with anisodamine combined with plasma exchange,while the control group was treated only with plasma exchange.Changes of platelet counts before treatment and on days 2,5,12 and 21 after treatment as well as incidence of adverse reactions were observed in two groups.Clinical efficacy was compared.Results In the research group,healing rate was significantly higher and overall response rate was slightly higher than control group.On days 2,5, 12 and 21 after treatment,the platelet counts in both groups increased obviously.On days 2,5 and after treatment,the platelet count in research group was significantly greater than in control group. During treatment,no severe adverse reactions were observed in both groups.Conclusion Aniso-damine combined with plasma exchange can effectively accelerate the recovery of platelets in patients with TTP,reduce platelet consumption and microthrombosis and shows a significant efficacy and better safety.
出处 《实用临床医药杂志》 CAS 2014年第9期48-50,共3页 Journal of Clinical Medicine in Practice
基金 中国高校医学期刊临床专项资金(11321660)
关键词 血小板变化 山莨菪碱 血浆置换 血栓性血小板减少性紫癜 platelet changes anisodamine plasma exchange thrombotic thrombocy-topenic purpura
  • 相关文献

参考文献13

  • 1MewarD, Wilson A G. Auto- antibodies inrheuma- toidarthritis: a review[J]. Biomed Phamacother, 2006, 60 (10): 648.
  • 2Duffy S M, Coyle T E. Platelet transfusions and bleeding complications associated with plasma exchange catheter place- ment in patients with presumed thrombotic thrornbocytopenic purpura[J]. J Clin Apher, 2013, 28(5): 356.
  • 3汪明性.药理学[M].4版.北京:人民卫生出版社,1997:208.
  • 4Femdndez - Pajarin G, Arias - Rivas S, Pias - Peleteiro J M. Aphasia and thromboeytopenic thrombotic purpura in a young woman: the platelet count dilemma[J ]. Rev Neurol, 2013, 57(7): 335.
  • 5LubanS, Li Z G. Citrullinated peptide and its relevance to rheumatoid arthritis: an update[J]. Int J RheumDis, 2010, 13(4) : 284.
  • 6Furuya T, Matsumoto I, Tsuchiya N, et al. Anti- glucose 6 - phosphate isomerase, anti - cyclic citrullinated peptide antibodies and HLA - DRB1 genotypes in Japanese patients with early rheumatoid arthritis [J ]. Clin Exp Rheumatol, 2008, 26(5): 918.
  • 7Shah N, Rutherford C, Matevosyan K, et al. Role of ADAMTSI3 in the management of thrombotic microan- giopathies including thrombotic thrombocytopenic purpura (TTP)[J]. BrJ Haematol, 2013, 163(4): 514.
  • 8Manro M, Kim J, Costello C, et al. Role of transforming growth factor betal in microvascular endothelial cell apoptosis associated with thrombotic thrombocytopenic purpura and hemolytic uremie syndrome[J]. Am J Hematol, 2001, 66 (1): 12.
  • 9杨永泉,李薇,张速林,曾兰兰.6-磷酸葡萄糖异构酶检测对类风湿关节炎的诊断意义[J].广东医学,2010,31(4):475-476. 被引量:7
  • 10Murrin R J, Murray J A. Thrombotic thrombocytopenic pur- pura: aetiology, pathophysiology and treatment [ J ]. Blood Rev, 2006, 20(1): 51.

二级参考文献13

  • 1董巍,张剑波,胡雪,房俊,周彬.抗环瓜氨酸肽抗体测定对类风湿关节炎诊断的临床价值[J].实用医院临床杂志,2005,2(1):84-86. 被引量:12
  • 2卿之驹,贾凯,秦立新.葡萄糖6-磷酸异构酶在类风湿关节炎中的诊断意义[J].实用预防医学,2005,12(3):481-482. 被引量:43
  • 3曾晓颖,沈志祥.血栓性血小板减少性紫癜的发病机理和有关实验室检查的评价[J].内科急危重症杂志,1996,2(3):129-129. 被引量:3
  • 4SCHALLER M, BURTON D R, DITZEL H J. Autoantibodies to GPI in rheumatoid arthritis: linkage between an animal model and humandisease[J]. Nat Immunol, 2001, 2(8): 746-753.
  • 5AMETT F C, EDVARTHY S M, BLOCH D A, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis[J]. Arthritis Rheum, 1988, 31(3): 315 -324.
  • 6GROOTENBOER MIGNOT S, NICAISE ROLAND P, DELAUNAY C, et al. Second generation anti - eyclic citrullinated peptide ( anti - CCP2 ) antibodies can replace other anti - filaggrin anti- bodies and improve rheumatoid arthritis diagnosis [ J ]. Scand J Rheumatol, 2004, 33(4): 218-220.
  • 7Rock G,Porta C,Bobbi2Pallavicini E. Thrombotic thrombocytopenic purpura treatment in year 2000[J].Haematologica,2000.410.
  • 8张之南.血液病诊断及疗效标准[S]北京:北京科学技术出版社,1998285-289.
  • 9Kakishta E. Pathophysiology and treatment of thrombotic thrombocy2topenic purpura/hemolytic syndrome (TTP/HUS)[J].Int J Hematolo2gy,2000.320.
  • 10Moake J L,Chow T W. Thrombotic thrombocytopenic purpura:under2standing a diseatse nl longer rare[J].American Journal of the Medical Sciences,1998.105.

共引文献38

同被引文献45

引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部